Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 24-2351 (Fed. Cir. Mar. 14, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Regeneron Pharmaceuticals, Inc. (“Regeneron”) ap- peals from a decision of the United States District Court for the Northern District of West Virginia denying Regen- eron’s motion for a preliminary injunction. In re Aflibercept Pat. Litig., No. 1:24-md-3103, 2024 WL 4958308 (N.D. W. Va. Oct. 1, 2024) (“Amgen Decision”).1 For the following reasons, we affirm. 1 The case generating this appeal is Regeneron Phar- maceuticals, Inc. v. Amgen, Inc., No.